- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/64 - Relaxins
Patent holdings for IPC class C07K 14/64
Total number of patents in this class: 115
10-year publication summary
8
|
10
|
11
|
15
|
7
|
11
|
8
|
12
|
11
|
1
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Ambrx, Inc. | 181 |
14 |
Bristol-myers Squibb Company | 4879 |
9 |
MedImmune Limited | 614 |
9 |
Sanofi | 4036 |
9 |
The Scripps Research Institute | 1347 |
8 |
Immatics Biotechnologies GmbH | 1155 |
5 |
Modernatx, Inc. | 1263 |
5 |
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | 9 |
5 |
Chemical & Biopharmaceutical Laboratories of Patras S.A. | 28 |
4 |
Florey Institute of Neuroscience and Mental Health | 42 |
4 |
Eli Lilly and Company | 3832 |
3 |
Howard Florey Institute of Experimental Physiology and Medicine | 17 |
3 |
River 2 Renal Corp. | 3 |
3 |
Tectonic Operating Company, Inc. | 5 |
3 |
Bayer Intellectual Property GmbH | 2509 |
2 |
Adaptimmune Limited | 188 |
2 |
National University of Singapore | 2436 |
2 |
Tectonic Therapeutic, Inc. | 4 |
2 |
F. Hoffmann-La Roche AG | 7934 |
1 |
AstraZeneca AB | 2928 |
1 |
Other owners | 21 |